The FDA Oncologic Drugs Advisory Committee recommended against approval of the Novartis agent Farydak (panobinostat), a pan-deacetylase inhibitor, for the indication of previously treated multiple myeloma when used in combination with bortezomib and dexamethasone.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe